The FDA on Tuesday approved etuvetidigene autotemcel (Waskyra) as the first cell-based gene therapy for patients 6 months and ...

The U.S. Food and Drug Administration has approved Waskyra (etuvetidigene autotemcel), the first cell-based gene therapy for ...

Based on insights from Towards Packaging, the global cell therapy packaging market will likely grow from USD 419.57 million ...

Second FDA designation for SENTI-202 this year, after Orphan Drug Designation, is supported by clinical data showing deep and durable complete remission rates combined with a well-tolerated safety ...

ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ...

Representing a variety of public and private sectors, guests from technology and finance to education and the ...

December 4, 2025) - Frost & Sullivan has released the "2025 White Paper on the Current Landscape and Future Trends of the Mitochondrial Medicine Industry" (hereinafter referred to as the "White Paper" ...

In the 1980s, the human immunodeficiency virus (HIV) was a global scourge, decimating communities. When it was identified in the blood products supply chain, people were terrified.

The global bioconjugation market is projected to grow at an estimated CAGR of close to 13% over the next five years. This growth is fueled by the rising need for targeted therapies, continuous ...

The gene editing market is experiencing significant growth, with a projected annual growth rate (CAGR) of 16-18% in the coming years. This expansion is fueled by breakthroughs in gene-editing ...